nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxazosin—ABCB1—lung cancer	0.184	1	CbGaD
Doxazosin—ORM1—Gefitinib—lung cancer	0.113	0.22	CbGbCtD
Doxazosin—ORM1—Erlotinib—lung cancer	0.0667	0.13	CbGbCtD
Doxazosin—CYP2C19—Gefitinib—lung cancer	0.0308	0.06	CbGbCtD
Doxazosin—CYP2C19—Teniposide—lung cancer	0.0298	0.0582	CbGbCtD
Doxazosin—ABCB1—Topotecan—lung cancer	0.0271	0.0529	CbGbCtD
Doxazosin—ABCB1—Gefitinib—lung cancer	0.0248	0.0484	CbGbCtD
Doxazosin—CYP2D6—Gefitinib—lung cancer	0.0234	0.0456	CbGbCtD
Doxazosin—ABCB1—Vinorelbine—lung cancer	0.0191	0.0373	CbGbCtD
Doxazosin—CYP2D6—Vinorelbine—lung cancer	0.018	0.0351	CbGbCtD
Doxazosin—ABCB1—Crizotinib—lung cancer	0.0152	0.0297	CbGbCtD
Doxazosin—ABCB1—Gemcitabine—lung cancer	0.0149	0.029	CbGbCtD
Doxazosin—ABCB1—Erlotinib—lung cancer	0.0147	0.0286	CbGbCtD
Doxazosin—CYP2D6—Erlotinib—lung cancer	0.0138	0.027	CbGbCtD
Doxazosin—ABCB1—Paclitaxel—lung cancer	0.0134	0.0262	CbGbCtD
Doxazosin—ABCB1—Irinotecan—lung cancer	0.0133	0.0258	CbGbCtD
Doxazosin—ABCB1—Vinblastine—lung cancer	0.0118	0.023	CbGbCtD
Doxazosin—CYP2D6—Vinblastine—lung cancer	0.0111	0.0216	CbGbCtD
Doxazosin—ABCB1—Cisplatin—lung cancer	0.0108	0.0211	CbGbCtD
Doxazosin—ABCB1—Etoposide—lung cancer	0.0106	0.0207	CbGbCtD
Doxazosin—ABCB1—Docetaxel—lung cancer	0.00971	0.0189	CbGbCtD
Doxazosin—ABCB1—Doxorubicin—lung cancer	0.00724	0.0141	CbGbCtD
Doxazosin—ABCB1—Methotrexate—lung cancer	0.00701	0.0137	CbGbCtD
Doxazosin—CYP2D6—Doxorubicin—lung cancer	0.00682	0.0133	CbGbCtD
Doxazosin—Prazosin—MT3—lung cancer	0.00386	0.642	CrCbGaD
Doxazosin—Prazosin—ABCG2—lung cancer	0.000766	0.127	CrCbGaD
Doxazosin—Prazosin—CYP1A1—lung cancer	0.0006	0.0998	CrCbGaD
Doxazosin—Terazosin—ABCB1—lung cancer	0.000465	0.0774	CrCbGaD
Doxazosin—Prazosin—ABCB1—lung cancer	0.000319	0.053	CrCbGaD
Doxazosin—Convulsion—Docetaxel—lung cancer	8.87e-05	0.000387	CcSEcCtD
Doxazosin—Paraesthesia—Paclitaxel—lung cancer	8.85e-05	0.000386	CcSEcCtD
Doxazosin—Hypertension—Docetaxel—lung cancer	8.83e-05	0.000386	CcSEcCtD
Doxazosin—Bronchitis—Doxorubicin—lung cancer	8.81e-05	0.000385	CcSEcCtD
Doxazosin—Dyspnoea—Paclitaxel—lung cancer	8.78e-05	0.000383	CcSEcCtD
Doxazosin—Somnolence—Paclitaxel—lung cancer	8.76e-05	0.000382	CcSEcCtD
Doxazosin—Decreased appetite—Etoposide—lung cancer	8.74e-05	0.000381	CcSEcCtD
Doxazosin—Chest pain—Docetaxel—lung cancer	8.71e-05	0.00038	CcSEcCtD
Doxazosin—Arthralgia—Docetaxel—lung cancer	8.71e-05	0.00038	CcSEcCtD
Doxazosin—Myalgia—Docetaxel—lung cancer	8.71e-05	0.00038	CcSEcCtD
Doxazosin—Nausea—Vinorelbine—lung cancer	8.7e-05	0.00038	CcSEcCtD
Doxazosin—Dyspepsia—Paclitaxel—lung cancer	8.67e-05	0.000379	CcSEcCtD
Doxazosin—Body temperature increased—Cisplatin—lung cancer	8.67e-05	0.000379	CcSEcCtD
Doxazosin—Asthenia—Irinotecan—lung cancer	8.67e-05	0.000378	CcSEcCtD
Doxazosin—Fatigue—Etoposide—lung cancer	8.66e-05	0.000378	CcSEcCtD
Doxazosin—Pain—Etoposide—lung cancer	8.59e-05	0.000375	CcSEcCtD
Doxazosin—Constipation—Etoposide—lung cancer	8.59e-05	0.000375	CcSEcCtD
Doxazosin—Dysuria—Doxorubicin—lung cancer	8.57e-05	0.000374	CcSEcCtD
Doxazosin—Neutropenia—Doxorubicin—lung cancer	8.57e-05	0.000374	CcSEcCtD
Doxazosin—Decreased appetite—Paclitaxel—lung cancer	8.56e-05	0.000374	CcSEcCtD
Doxazosin—Dry mouth—Docetaxel—lung cancer	8.52e-05	0.000372	CcSEcCtD
Doxazosin—Upper respiratory tract infection—Doxorubicin—lung cancer	8.52e-05	0.000372	CcSEcCtD
Doxazosin—Fatigue—Paclitaxel—lung cancer	8.49e-05	0.000371	CcSEcCtD
Doxazosin—Hepatitis—Methotrexate—lung cancer	8.47e-05	0.00037	CcSEcCtD
Doxazosin—Pollakiuria—Doxorubicin—lung cancer	8.47e-05	0.00037	CcSEcCtD
Doxazosin—Asthenia—Gemcitabine—lung cancer	8.44e-05	0.000369	CcSEcCtD
Doxazosin—Pain—Paclitaxel—lung cancer	8.43e-05	0.000368	CcSEcCtD
Doxazosin—Constipation—Paclitaxel—lung cancer	8.43e-05	0.000368	CcSEcCtD
Doxazosin—Confusional state—Docetaxel—lung cancer	8.42e-05	0.000368	CcSEcCtD
Doxazosin—Pharyngitis—Methotrexate—lung cancer	8.41e-05	0.000367	CcSEcCtD
Doxazosin—Photosensitivity reaction—Doxorubicin—lung cancer	8.37e-05	0.000365	CcSEcCtD
Doxazosin—Oedema—Docetaxel—lung cancer	8.35e-05	0.000365	CcSEcCtD
Doxazosin—Weight increased—Doxorubicin—lung cancer	8.34e-05	0.000364	CcSEcCtD
Doxazosin—Pruritus—Gemcitabine—lung cancer	8.33e-05	0.000363	CcSEcCtD
Doxazosin—Infection—Docetaxel—lung cancer	8.3e-05	0.000362	CcSEcCtD
Doxazosin—Weight decreased—Doxorubicin—lung cancer	8.29e-05	0.000362	CcSEcCtD
Doxazosin—Feeling abnormal—Etoposide—lung cancer	8.28e-05	0.000361	CcSEcCtD
Doxazosin—Hyperglycaemia—Doxorubicin—lung cancer	8.27e-05	0.000361	CcSEcCtD
Doxazosin—Diarrhoea—Irinotecan—lung cancer	8.27e-05	0.000361	CcSEcCtD
Doxazosin—Pneumonia—Doxorubicin—lung cancer	8.22e-05	0.000359	CcSEcCtD
Doxazosin—Gastrointestinal pain—Etoposide—lung cancer	8.22e-05	0.000359	CcSEcCtD
Doxazosin—Shock—Docetaxel—lung cancer	8.22e-05	0.000359	CcSEcCtD
Doxazosin—Thrombocytopenia—Docetaxel—lung cancer	8.18e-05	0.000357	CcSEcCtD
Doxazosin—Drowsiness—Doxorubicin—lung cancer	8.17e-05	0.000357	CcSEcCtD
Doxazosin—Visual impairment—Methotrexate—lung cancer	8.16e-05	0.000356	CcSEcCtD
Doxazosin—Tachycardia—Docetaxel—lung cancer	8.15e-05	0.000356	CcSEcCtD
Doxazosin—Feeling abnormal—Paclitaxel—lung cancer	8.12e-05	0.000354	CcSEcCtD
Doxazosin—Skin disorder—Docetaxel—lung cancer	8.11e-05	0.000354	CcSEcCtD
Doxazosin—Hypersensitivity—Cisplatin—lung cancer	8.08e-05	0.000353	CcSEcCtD
Doxazosin—Gastrointestinal pain—Paclitaxel—lung cancer	8.06e-05	0.000352	CcSEcCtD
Doxazosin—Diarrhoea—Gemcitabine—lung cancer	8.05e-05	0.000351	CcSEcCtD
Doxazosin—Dizziness—Irinotecan—lung cancer	7.99e-05	0.000349	CcSEcCtD
Doxazosin—Urticaria—Etoposide—lung cancer	7.98e-05	0.000348	CcSEcCtD
Doxazosin—Jaundice—Doxorubicin—lung cancer	7.97e-05	0.000348	CcSEcCtD
Doxazosin—Anorexia—Docetaxel—lung cancer	7.96e-05	0.000347	CcSEcCtD
Doxazosin—Abdominal pain—Etoposide—lung cancer	7.94e-05	0.000347	CcSEcCtD
Doxazosin—Body temperature increased—Etoposide—lung cancer	7.94e-05	0.000347	CcSEcCtD
Doxazosin—Urinary tract infection—Doxorubicin—lung cancer	7.94e-05	0.000347	CcSEcCtD
Doxazosin—Conjunctivitis—Doxorubicin—lung cancer	7.94e-05	0.000347	CcSEcCtD
Doxazosin—Eye disorder—Methotrexate—lung cancer	7.92e-05	0.000346	CcSEcCtD
Doxazosin—Tinnitus—Methotrexate—lung cancer	7.9e-05	0.000345	CcSEcCtD
Doxazosin—Asthenia—Cisplatin—lung cancer	7.87e-05	0.000344	CcSEcCtD
Doxazosin—Sweating—Doxorubicin—lung cancer	7.83e-05	0.000342	CcSEcCtD
Doxazosin—Urticaria—Paclitaxel—lung cancer	7.83e-05	0.000342	CcSEcCtD
Doxazosin—Hypotension—Docetaxel—lung cancer	7.8e-05	0.000341	CcSEcCtD
Doxazosin—Haematuria—Doxorubicin—lung cancer	7.79e-05	0.00034	CcSEcCtD
Doxazosin—Body temperature increased—Paclitaxel—lung cancer	7.79e-05	0.00034	CcSEcCtD
Doxazosin—Abdominal pain—Paclitaxel—lung cancer	7.79e-05	0.00034	CcSEcCtD
Doxazosin—Epistaxis—Doxorubicin—lung cancer	7.71e-05	0.000336	CcSEcCtD
Doxazosin—Vomiting—Irinotecan—lung cancer	7.68e-05	0.000335	CcSEcCtD
Doxazosin—Sinusitis—Doxorubicin—lung cancer	7.67e-05	0.000335	CcSEcCtD
Doxazosin—Rash—Irinotecan—lung cancer	7.62e-05	0.000333	CcSEcCtD
Doxazosin—Dermatitis—Irinotecan—lung cancer	7.61e-05	0.000332	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Docetaxel—lung cancer	7.61e-05	0.000332	CcSEcCtD
Doxazosin—Chills—Methotrexate—lung cancer	7.6e-05	0.000332	CcSEcCtD
Doxazosin—Headache—Irinotecan—lung cancer	7.57e-05	0.00033	CcSEcCtD
Doxazosin—Insomnia—Docetaxel—lung cancer	7.55e-05	0.00033	CcSEcCtD
Doxazosin—Diarrhoea—Cisplatin—lung cancer	7.5e-05	0.000328	CcSEcCtD
Doxazosin—Paraesthesia—Docetaxel—lung cancer	7.5e-05	0.000327	CcSEcCtD
Doxazosin—Alopecia—Methotrexate—lung cancer	7.49e-05	0.000327	CcSEcCtD
Doxazosin—Vomiting—Gemcitabine—lung cancer	7.48e-05	0.000327	CcSEcCtD
Doxazosin—Bradycardia—Doxorubicin—lung cancer	7.47e-05	0.000326	CcSEcCtD
Doxazosin—Dyspnoea—Docetaxel—lung cancer	7.45e-05	0.000325	CcSEcCtD
Doxazosin—Somnolence—Docetaxel—lung cancer	7.42e-05	0.000324	CcSEcCtD
Doxazosin—Mental disorder—Methotrexate—lung cancer	7.42e-05	0.000324	CcSEcCtD
Doxazosin—Rash—Gemcitabine—lung cancer	7.42e-05	0.000324	CcSEcCtD
Doxazosin—Dermatitis—Gemcitabine—lung cancer	7.41e-05	0.000324	CcSEcCtD
Doxazosin—Hypersensitivity—Etoposide—lung cancer	7.4e-05	0.000323	CcSEcCtD
Doxazosin—Malnutrition—Methotrexate—lung cancer	7.37e-05	0.000322	CcSEcCtD
Doxazosin—Headache—Gemcitabine—lung cancer	7.37e-05	0.000322	CcSEcCtD
Doxazosin—Rhinitis—Doxorubicin—lung cancer	7.35e-05	0.000321	CcSEcCtD
Doxazosin—Dyspepsia—Docetaxel—lung cancer	7.35e-05	0.000321	CcSEcCtD
Doxazosin—Hepatitis—Doxorubicin—lung cancer	7.34e-05	0.00032	CcSEcCtD
Doxazosin—Hypoaesthesia—Doxorubicin—lung cancer	7.3e-05	0.000319	CcSEcCtD
Doxazosin—Pharyngitis—Doxorubicin—lung cancer	7.28e-05	0.000318	CcSEcCtD
Doxazosin—Decreased appetite—Docetaxel—lung cancer	7.26e-05	0.000317	CcSEcCtD
Doxazosin—Hypersensitivity—Paclitaxel—lung cancer	7.26e-05	0.000317	CcSEcCtD
Doxazosin—Dysgeusia—Methotrexate—lung cancer	7.22e-05	0.000315	CcSEcCtD
Doxazosin—Asthenia—Etoposide—lung cancer	7.21e-05	0.000315	CcSEcCtD
Doxazosin—Fatigue—Docetaxel—lung cancer	7.2e-05	0.000314	CcSEcCtD
Doxazosin—Nausea—Irinotecan—lung cancer	7.18e-05	0.000313	CcSEcCtD
Doxazosin—Constipation—Docetaxel—lung cancer	7.14e-05	0.000312	CcSEcCtD
Doxazosin—Pain—Docetaxel—lung cancer	7.14e-05	0.000312	CcSEcCtD
Doxazosin—Back pain—Methotrexate—lung cancer	7.13e-05	0.000311	CcSEcCtD
Doxazosin—Pruritus—Etoposide—lung cancer	7.11e-05	0.00031	CcSEcCtD
Doxazosin—Visual impairment—Doxorubicin—lung cancer	7.07e-05	0.000309	CcSEcCtD
Doxazosin—Asthenia—Paclitaxel—lung cancer	7.07e-05	0.000309	CcSEcCtD
Doxazosin—Nausea—Gemcitabine—lung cancer	6.99e-05	0.000305	CcSEcCtD
Doxazosin—Vomiting—Cisplatin—lung cancer	6.97e-05	0.000304	CcSEcCtD
Doxazosin—Pruritus—Paclitaxel—lung cancer	6.97e-05	0.000304	CcSEcCtD
Doxazosin—Vision blurred—Methotrexate—lung cancer	6.95e-05	0.000303	CcSEcCtD
Doxazosin—Rash—Cisplatin—lung cancer	6.92e-05	0.000302	CcSEcCtD
Doxazosin—Dermatitis—Cisplatin—lung cancer	6.91e-05	0.000302	CcSEcCtD
Doxazosin—Feeling abnormal—Docetaxel—lung cancer	6.88e-05	0.0003	CcSEcCtD
Doxazosin—Diarrhoea—Etoposide—lung cancer	6.88e-05	0.0003	CcSEcCtD
Doxazosin—Eye disorder—Doxorubicin—lung cancer	6.86e-05	0.000299	CcSEcCtD
Doxazosin—Ill-defined disorder—Methotrexate—lung cancer	6.84e-05	0.000299	CcSEcCtD
Doxazosin—Tinnitus—Doxorubicin—lung cancer	6.84e-05	0.000299	CcSEcCtD
Doxazosin—Gastrointestinal pain—Docetaxel—lung cancer	6.83e-05	0.000298	CcSEcCtD
Doxazosin—Flushing—Doxorubicin—lung cancer	6.81e-05	0.000297	CcSEcCtD
Doxazosin—Diarrhoea—Paclitaxel—lung cancer	6.74e-05	0.000294	CcSEcCtD
Doxazosin—Malaise—Methotrexate—lung cancer	6.65e-05	0.00029	CcSEcCtD
Doxazosin—Dizziness—Etoposide—lung cancer	6.64e-05	0.00029	CcSEcCtD
Doxazosin—Vertigo—Methotrexate—lung cancer	6.63e-05	0.000289	CcSEcCtD
Doxazosin—Abdominal pain—Docetaxel—lung cancer	6.6e-05	0.000288	CcSEcCtD
Doxazosin—Body temperature increased—Docetaxel—lung cancer	6.6e-05	0.000288	CcSEcCtD
Doxazosin—Leukopenia—Methotrexate—lung cancer	6.6e-05	0.000288	CcSEcCtD
Doxazosin—Chills—Doxorubicin—lung cancer	6.58e-05	0.000287	CcSEcCtD
Doxazosin—Arrhythmia—Doxorubicin—lung cancer	6.55e-05	0.000286	CcSEcCtD
Doxazosin—Dizziness—Paclitaxel—lung cancer	6.52e-05	0.000284	CcSEcCtD
Doxazosin—Nausea—Cisplatin—lung cancer	6.52e-05	0.000284	CcSEcCtD
Doxazosin—Alopecia—Doxorubicin—lung cancer	6.48e-05	0.000283	CcSEcCtD
Doxazosin—Cough—Methotrexate—lung cancer	6.44e-05	0.000281	CcSEcCtD
Doxazosin—Mental disorder—Doxorubicin—lung cancer	6.43e-05	0.000281	CcSEcCtD
Doxazosin—Convulsion—Methotrexate—lung cancer	6.39e-05	0.000279	CcSEcCtD
Doxazosin—Vomiting—Etoposide—lung cancer	6.39e-05	0.000279	CcSEcCtD
Doxazosin—Malnutrition—Doxorubicin—lung cancer	6.39e-05	0.000279	CcSEcCtD
Doxazosin—Rash—Etoposide—lung cancer	6.34e-05	0.000277	CcSEcCtD
Doxazosin—Dermatitis—Etoposide—lung cancer	6.33e-05	0.000276	CcSEcCtD
Doxazosin—Headache—Etoposide—lung cancer	6.3e-05	0.000275	CcSEcCtD
Doxazosin—Flatulence—Doxorubicin—lung cancer	6.29e-05	0.000275	CcSEcCtD
Doxazosin—Chest pain—Methotrexate—lung cancer	6.28e-05	0.000274	CcSEcCtD
Doxazosin—Arthralgia—Methotrexate—lung cancer	6.28e-05	0.000274	CcSEcCtD
Doxazosin—Myalgia—Methotrexate—lung cancer	6.28e-05	0.000274	CcSEcCtD
Doxazosin—Tension—Doxorubicin—lung cancer	6.27e-05	0.000274	CcSEcCtD
Doxazosin—Vomiting—Paclitaxel—lung cancer	6.26e-05	0.000273	CcSEcCtD
Doxazosin—Dysgeusia—Doxorubicin—lung cancer	6.25e-05	0.000273	CcSEcCtD
Doxazosin—Rash—Paclitaxel—lung cancer	6.21e-05	0.000271	CcSEcCtD
Doxazosin—Dermatitis—Paclitaxel—lung cancer	6.21e-05	0.000271	CcSEcCtD
Doxazosin—Discomfort—Methotrexate—lung cancer	6.2e-05	0.000271	CcSEcCtD
Doxazosin—Nervousness—Doxorubicin—lung cancer	6.2e-05	0.000271	CcSEcCtD
Doxazosin—Back pain—Doxorubicin—lung cancer	6.18e-05	0.00027	CcSEcCtD
Doxazosin—Headache—Paclitaxel—lung cancer	6.17e-05	0.000269	CcSEcCtD
Doxazosin—Hypersensitivity—Docetaxel—lung cancer	6.15e-05	0.000269	CcSEcCtD
Doxazosin—Muscle spasms—Doxorubicin—lung cancer	6.14e-05	0.000268	CcSEcCtD
Doxazosin—Confusional state—Methotrexate—lung cancer	6.07e-05	0.000265	CcSEcCtD
Doxazosin—Vision blurred—Doxorubicin—lung cancer	6.02e-05	0.000263	CcSEcCtD
Doxazosin—Asthenia—Docetaxel—lung cancer	5.99e-05	0.000262	CcSEcCtD
Doxazosin—Infection—Methotrexate—lung cancer	5.98e-05	0.000261	CcSEcCtD
Doxazosin—Nausea—Etoposide—lung cancer	5.97e-05	0.000261	CcSEcCtD
Doxazosin—Ill-defined disorder—Doxorubicin—lung cancer	5.93e-05	0.000259	CcSEcCtD
Doxazosin—Pruritus—Docetaxel—lung cancer	5.91e-05	0.000258	CcSEcCtD
Doxazosin—Thrombocytopenia—Methotrexate—lung cancer	5.89e-05	0.000257	CcSEcCtD
Doxazosin—Agitation—Doxorubicin—lung cancer	5.87e-05	0.000256	CcSEcCtD
Doxazosin—Nausea—Paclitaxel—lung cancer	5.85e-05	0.000255	CcSEcCtD
Doxazosin—Skin disorder—Methotrexate—lung cancer	5.85e-05	0.000255	CcSEcCtD
Doxazosin—Hyperhidrosis—Methotrexate—lung cancer	5.82e-05	0.000254	CcSEcCtD
Doxazosin—Malaise—Doxorubicin—lung cancer	5.76e-05	0.000251	CcSEcCtD
Doxazosin—Vertigo—Doxorubicin—lung cancer	5.74e-05	0.00025	CcSEcCtD
Doxazosin—Anorexia—Methotrexate—lung cancer	5.74e-05	0.00025	CcSEcCtD
Doxazosin—Syncope—Doxorubicin—lung cancer	5.73e-05	0.00025	CcSEcCtD
Doxazosin—Leukopenia—Doxorubicin—lung cancer	5.72e-05	0.00025	CcSEcCtD
Doxazosin—Diarrhoea—Docetaxel—lung cancer	5.71e-05	0.000249	CcSEcCtD
Doxazosin—Palpitations—Doxorubicin—lung cancer	5.64e-05	0.000246	CcSEcCtD
Doxazosin—Hypotension—Methotrexate—lung cancer	5.62e-05	0.000246	CcSEcCtD
Doxazosin—Loss of consciousness—Doxorubicin—lung cancer	5.61e-05	0.000245	CcSEcCtD
Doxazosin—Cough—Doxorubicin—lung cancer	5.57e-05	0.000243	CcSEcCtD
Doxazosin—Convulsion—Doxorubicin—lung cancer	5.53e-05	0.000242	CcSEcCtD
Doxazosin—Dizziness—Docetaxel—lung cancer	5.52e-05	0.000241	CcSEcCtD
Doxazosin—Hypertension—Doxorubicin—lung cancer	5.51e-05	0.000241	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Methotrexate—lung cancer	5.48e-05	0.000239	CcSEcCtD
Doxazosin—Insomnia—Methotrexate—lung cancer	5.44e-05	0.000238	CcSEcCtD
Doxazosin—Chest pain—Doxorubicin—lung cancer	5.44e-05	0.000237	CcSEcCtD
Doxazosin—Arthralgia—Doxorubicin—lung cancer	5.44e-05	0.000237	CcSEcCtD
Doxazosin—Myalgia—Doxorubicin—lung cancer	5.44e-05	0.000237	CcSEcCtD
Doxazosin—Anxiety—Doxorubicin—lung cancer	5.42e-05	0.000237	CcSEcCtD
Doxazosin—Paraesthesia—Methotrexate—lung cancer	5.4e-05	0.000236	CcSEcCtD
Doxazosin—Discomfort—Doxorubicin—lung cancer	5.37e-05	0.000234	CcSEcCtD
Doxazosin—Dyspnoea—Methotrexate—lung cancer	5.37e-05	0.000234	CcSEcCtD
Doxazosin—Somnolence—Methotrexate—lung cancer	5.35e-05	0.000234	CcSEcCtD
Doxazosin—Dry mouth—Doxorubicin—lung cancer	5.32e-05	0.000232	CcSEcCtD
Doxazosin—Vomiting—Docetaxel—lung cancer	5.31e-05	0.000232	CcSEcCtD
Doxazosin—Dyspepsia—Methotrexate—lung cancer	5.3e-05	0.000231	CcSEcCtD
Doxazosin—Rash—Docetaxel—lung cancer	5.27e-05	0.00023	CcSEcCtD
Doxazosin—Dermatitis—Docetaxel—lung cancer	5.26e-05	0.00023	CcSEcCtD
Doxazosin—Confusional state—Doxorubicin—lung cancer	5.26e-05	0.000229	CcSEcCtD
Doxazosin—Decreased appetite—Methotrexate—lung cancer	5.23e-05	0.000228	CcSEcCtD
Doxazosin—Headache—Docetaxel—lung cancer	5.23e-05	0.000228	CcSEcCtD
Doxazosin—Oedema—Doxorubicin—lung cancer	5.21e-05	0.000228	CcSEcCtD
Doxazosin—Fatigue—Methotrexate—lung cancer	5.19e-05	0.000227	CcSEcCtD
Doxazosin—Infection—Doxorubicin—lung cancer	5.18e-05	0.000226	CcSEcCtD
Doxazosin—Pain—Methotrexate—lung cancer	5.15e-05	0.000225	CcSEcCtD
Doxazosin—Shock—Doxorubicin—lung cancer	5.13e-05	0.000224	CcSEcCtD
Doxazosin—Thrombocytopenia—Doxorubicin—lung cancer	5.1e-05	0.000223	CcSEcCtD
Doxazosin—Tachycardia—Doxorubicin—lung cancer	5.09e-05	0.000222	CcSEcCtD
Doxazosin—Skin disorder—Doxorubicin—lung cancer	5.06e-05	0.000221	CcSEcCtD
Doxazosin—Hyperhidrosis—Doxorubicin—lung cancer	5.04e-05	0.00022	CcSEcCtD
Doxazosin—Anorexia—Doxorubicin—lung cancer	4.97e-05	0.000217	CcSEcCtD
Doxazosin—Nausea—Docetaxel—lung cancer	4.96e-05	0.000217	CcSEcCtD
Doxazosin—Feeling abnormal—Methotrexate—lung cancer	4.96e-05	0.000217	CcSEcCtD
Doxazosin—Gastrointestinal pain—Methotrexate—lung cancer	4.92e-05	0.000215	CcSEcCtD
Doxazosin—Hypotension—Doxorubicin—lung cancer	4.87e-05	0.000213	CcSEcCtD
Doxazosin—Urticaria—Methotrexate—lung cancer	4.78e-05	0.000209	CcSEcCtD
Doxazosin—Abdominal pain—Methotrexate—lung cancer	4.76e-05	0.000208	CcSEcCtD
Doxazosin—Body temperature increased—Methotrexate—lung cancer	4.76e-05	0.000208	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Doxorubicin—lung cancer	4.75e-05	0.000207	CcSEcCtD
Doxazosin—Insomnia—Doxorubicin—lung cancer	4.71e-05	0.000206	CcSEcCtD
Doxazosin—Paraesthesia—Doxorubicin—lung cancer	4.68e-05	0.000204	CcSEcCtD
Doxazosin—Dyspnoea—Doxorubicin—lung cancer	4.65e-05	0.000203	CcSEcCtD
Doxazosin—Somnolence—Doxorubicin—lung cancer	4.63e-05	0.000202	CcSEcCtD
Doxazosin—Dyspepsia—Doxorubicin—lung cancer	4.59e-05	0.0002	CcSEcCtD
Doxazosin—Decreased appetite—Doxorubicin—lung cancer	4.53e-05	0.000198	CcSEcCtD
Doxazosin—Fatigue—Doxorubicin—lung cancer	4.49e-05	0.000196	CcSEcCtD
Doxazosin—Constipation—Doxorubicin—lung cancer	4.46e-05	0.000195	CcSEcCtD
Doxazosin—Pain—Doxorubicin—lung cancer	4.46e-05	0.000195	CcSEcCtD
Doxazosin—Hypersensitivity—Methotrexate—lung cancer	4.43e-05	0.000194	CcSEcCtD
Doxazosin—Asthenia—Methotrexate—lung cancer	4.32e-05	0.000189	CcSEcCtD
Doxazosin—Feeling abnormal—Doxorubicin—lung cancer	4.29e-05	0.000187	CcSEcCtD
Doxazosin—Gastrointestinal pain—Doxorubicin—lung cancer	4.26e-05	0.000186	CcSEcCtD
Doxazosin—Pruritus—Methotrexate—lung cancer	4.26e-05	0.000186	CcSEcCtD
Doxazosin—Urticaria—Doxorubicin—lung cancer	4.14e-05	0.000181	CcSEcCtD
Doxazosin—Abdominal pain—Doxorubicin—lung cancer	4.12e-05	0.00018	CcSEcCtD
Doxazosin—Body temperature increased—Doxorubicin—lung cancer	4.12e-05	0.00018	CcSEcCtD
Doxazosin—Diarrhoea—Methotrexate—lung cancer	4.12e-05	0.00018	CcSEcCtD
Doxazosin—Dizziness—Methotrexate—lung cancer	3.98e-05	0.000174	CcSEcCtD
Doxazosin—Hypersensitivity—Doxorubicin—lung cancer	3.84e-05	0.000168	CcSEcCtD
Doxazosin—Vomiting—Methotrexate—lung cancer	3.83e-05	0.000167	CcSEcCtD
Doxazosin—Rash—Methotrexate—lung cancer	3.8e-05	0.000166	CcSEcCtD
Doxazosin—Dermatitis—Methotrexate—lung cancer	3.79e-05	0.000166	CcSEcCtD
Doxazosin—Headache—Methotrexate—lung cancer	3.77e-05	0.000165	CcSEcCtD
Doxazosin—Asthenia—Doxorubicin—lung cancer	3.74e-05	0.000163	CcSEcCtD
Doxazosin—Pruritus—Doxorubicin—lung cancer	3.69e-05	0.000161	CcSEcCtD
Doxazosin—Nausea—Methotrexate—lung cancer	3.58e-05	0.000156	CcSEcCtD
Doxazosin—Diarrhoea—Doxorubicin—lung cancer	3.57e-05	0.000156	CcSEcCtD
Doxazosin—Dizziness—Doxorubicin—lung cancer	3.45e-05	0.00015	CcSEcCtD
Doxazosin—Vomiting—Doxorubicin—lung cancer	3.31e-05	0.000145	CcSEcCtD
Doxazosin—Rash—Doxorubicin—lung cancer	3.29e-05	0.000143	CcSEcCtD
Doxazosin—Dermatitis—Doxorubicin—lung cancer	3.28e-05	0.000143	CcSEcCtD
Doxazosin—Headache—Doxorubicin—lung cancer	3.27e-05	0.000143	CcSEcCtD
Doxazosin—Nausea—Doxorubicin—lung cancer	3.1e-05	0.000135	CcSEcCtD
Doxazosin—ABCB1—Metabolism—GSTP1—lung cancer	6.6e-06	9.75e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—KIT—lung cancer	6.6e-06	9.75e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—APC—lung cancer	6.6e-06	9.75e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PIK3CG—lung cancer	6.6e-06	9.75e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—NRAS—lung cancer	6.6e-06	9.75e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CAT—lung cancer	6.58e-06	9.72e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	6.55e-06	9.67e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—EGF—lung cancer	6.53e-06	9.64e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3CG—lung cancer	6.52e-06	9.62e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—IL2—lung cancer	6.49e-06	9.58e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—TERT—lung cancer	6.47e-06	9.55e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CAT—lung cancer	6.43e-06	9.49e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—APOA1—lung cancer	6.42e-06	9.49e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—ABCB1—lung cancer	6.4e-06	9.46e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—KDR—lung cancer	6.37e-06	9.4e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—MAPK3—lung cancer	6.32e-06	9.34e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—TYMS—lung cancer	6.29e-06	9.29e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—PIK3CA—lung cancer	6.29e-06	9.29e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—POMC—lung cancer	6.28e-06	9.28e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—FGFR1—lung cancer	6.28e-06	9.27e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MDM2—lung cancer	6.27e-06	9.25e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—RAF1—lung cancer	6.24e-06	9.22e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—GSTP1—lung cancer	6.22e-06	9.19e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—GSTM1—lung cancer	6.22e-06	9.18e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—BRAF—lung cancer	6.21e-06	9.16e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—POMC—lung cancer	6.2e-06	9.16e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—HIF1A—lung cancer	6.19e-06	9.13e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—ERBB2—lung cancer	6.18e-06	9.12e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—TYMS—lung cancer	6.14e-06	9.07e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Hemostasis—AKT1—lung cancer	6.13e-06	9.06e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IL6R—lung cancer	6.13e-06	9.05e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CREBBP—lung cancer	6.12e-06	9.04e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—PIK3CB—lung cancer	6.1e-06	9e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MTOR—lung cancer	6.1e-06	9e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—GSTM1—lung cancer	6.07e-06	8.96e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CAT—lung cancer	6.06e-06	8.94e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—CREBBP—lung cancer	6.04e-06	8.92e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—EGFR—lung cancer	6.02e-06	8.88e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—APOA1—lung cancer	5.97e-06	8.81e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—KDR—lung cancer	5.92e-06	8.73e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CYP1A1—lung cancer	5.89e-06	8.7e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ABCB1—lung cancer	5.89e-06	8.7e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3CG—lung cancer	5.86e-06	8.66e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—KIT—lung cancer	5.86e-06	8.66e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—APC—lung cancer	5.86e-06	8.66e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—NRAS—lung cancer	5.86e-06	8.66e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CXCL8—lung cancer	5.86e-06	8.65e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—ERCC2—lung cancer	5.85e-06	8.63e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MAP2K1—lung cancer	5.84e-06	8.63e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—HRAS—lung cancer	5.82e-06	8.59e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PIK3CD—lung cancer	5.8e-06	8.57e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EGF—lung cancer	5.8e-06	8.56e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—TYMS—lung cancer	5.79e-06	8.54e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CYP1A1—lung cancer	5.75e-06	8.49e-05	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—PIK3CA—lung cancer	5.75e-06	8.49e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3CD—lung cancer	5.73e-06	8.46e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—GSTM1—lung cancer	5.72e-06	8.44e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—ERCC2—lung cancer	5.71e-06	8.42e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—KRAS—lung cancer	5.68e-06	8.39e-05	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—AKT1—lung cancer	5.66e-06	8.36e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—ALB—lung cancer	5.66e-06	8.35e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—MAPK3—lung cancer	5.62e-06	8.29e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CASP3—lung cancer	5.61e-06	8.28e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—IL2—lung cancer	5.6e-06	8.27e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—POMC—lung cancer	5.58e-06	8.24e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—IL6—lung cancer	5.57e-06	8.22e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—BRAF—lung cancer	5.51e-06	8.14e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CCND1—lung cancer	5.46e-06	8.06e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	5.45e-06	8.05e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—APC—lung cancer	5.45e-06	8.05e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—KIT—lung cancer	5.45e-06	8.05e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—NRAS—lung cancer	5.45e-06	8.05e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IL6R—lung cancer	5.45e-06	8.04e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—JUN—lung cancer	5.45e-06	8.04e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CREBBP—lung cancer	5.44e-06	8.03e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CYP1A1—lung cancer	5.42e-06	8e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EGF—lung cancer	5.39e-06	7.95e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ERCC2—lung cancer	5.38e-06	7.94e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—EGFR—lung cancer	5.34e-06	7.89e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MMP9—lung cancer	5.3e-06	7.82e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CDKN1A—lung cancer	5.28e-06	7.79e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—PTEN—lung cancer	5.27e-06	7.78e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—PIK3CA—lung cancer	5.22e-06	7.71e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	5.22e-06	7.71e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MDM2—lung cancer	5.2e-06	7.68e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	5.19e-06	7.66e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—POMC—lung cancer	5.19e-06	7.66e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—RAF1—lung cancer	5.18e-06	7.65e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	5.16e-06	7.61e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—AKT1—lung cancer	5.14e-06	7.59e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—ERBB2—lung cancer	5.13e-06	7.57e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—BRAF—lung cancer	5.12e-06	7.56e-05	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	5.11e-06	7.54e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IL6R—lung cancer	5.06e-06	7.47e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MTOR—lung cancer	5.06e-06	7.47e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PIK3CB—lung cancer	5.06e-06	7.47e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—APOA1—lung cancer	5.06e-06	7.47e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CREBBP—lung cancer	5.05e-06	7.46e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—KRAS—lung cancer	5.05e-06	7.45e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—EP300—lung cancer	5.02e-06	7.42e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3CB—lung cancer	4.99e-06	7.37e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—EGFR—lung cancer	4.96e-06	7.33e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PTGS2—lung cancer	4.95e-06	7.31e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—APOA1—lung cancer	4.94e-06	7.29e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—SRC—lung cancer	4.88e-06	7.21e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CXCL8—lung cancer	4.86e-06	7.18e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.84e-06	7.15e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—HRAS—lung cancer	4.83e-06	7.13e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	4.82e-06	7.12e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	4.79e-06	7.07e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—VEGFA—lung cancer	4.76e-06	7.02e-05	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	4.74e-06	7.01e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—STAT3—lung cancer	4.71e-06	6.96e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—NRAS—lung cancer	4.7e-06	6.94e-05	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	4.7e-06	6.93e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—KRAS—lung cancer	4.69e-06	6.92e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CASP3—lung cancer	4.65e-06	6.87e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—APOA1—lung cancer	4.65e-06	6.87e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IL2—lung cancer	4.65e-06	6.86e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	4.64e-06	6.85e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—IL6—lung cancer	4.62e-06	6.83e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MDM2—lung cancer	4.62e-06	6.82e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3CG—lung cancer	4.62e-06	6.82e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—RAF1—lung cancer	4.6e-06	6.8e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—ERBB2—lung cancer	4.55e-06	6.72e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CCND1—lung cancer	4.53e-06	6.69e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—JUN—lung cancer	4.52e-06	6.67e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3CG—lung cancer	4.51e-06	6.65e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MAPK3—lung cancer	4.5e-06	6.65e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MTOR—lung cancer	4.49e-06	6.64e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	4.49e-06	6.64e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MMP9—lung cancer	4.4e-06	6.49e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—POMC—lung cancer	4.39e-06	6.49e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	4.38e-06	6.47e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MYC—lung cancer	4.38e-06	6.46e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PTEN—lung cancer	4.37e-06	6.45e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CXCL8—lung cancer	4.32e-06	6.38e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PTEN—lung cancer	4.31e-06	6.37e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	4.31e-06	6.36e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MDM2—lung cancer	4.29e-06	6.34e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—HRAS—lung cancer	4.29e-06	6.33e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—POMC—lung cancer	4.29e-06	6.33e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—EGFR—lung cancer	4.28e-06	6.32e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CREBBP—lung cancer	4.28e-06	6.32e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—RAF1—lung cancer	4.28e-06	6.31e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—AKT1—lung cancer	4.27e-06	6.3e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3CG—lung cancer	4.25e-06	6.27e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—ERBB2—lung cancer	4.23e-06	6.25e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CREBBP—lung cancer	4.18e-06	6.17e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MTOR—lung cancer	4.18e-06	6.17e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	4.18e-06	6.17e-05	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	4.17e-06	6.16e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—EP300—lung cancer	4.17e-06	6.16e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CASP3—lung cancer	4.13e-06	6.1e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IL2—lung cancer	4.13e-06	6.09e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—EP300—lung cancer	4.12e-06	6.08e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—IL6—lung cancer	4.11e-06	6.06e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3CD—lung cancer	4.06e-06	5.99e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—SRC—lung cancer	4.05e-06	5.99e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—KRAS—lung cancer	4.04e-06	5.97e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—POMC—lung cancer	4.04e-06	5.97e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CCND1—lung cancer	4.02e-06	5.94e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—JUN—lung cancer	4.01e-06	5.93e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CXCL8—lung cancer	4.01e-06	5.92e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—ALB—lung cancer	4.01e-06	5.92e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—HRAS—lung cancer	3.99e-06	5.89e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3CD—lung cancer	3.96e-06	5.85e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—VEGFA—lung cancer	3.95e-06	5.83e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CREBBP—lung cancer	3.94e-06	5.81e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—ALB—lung cancer	3.91e-06	5.77e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—STAT3—lung cancer	3.91e-06	5.77e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MMP9—lung cancer	3.91e-06	5.77e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—NRAS—lung cancer	3.9e-06	5.76e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	3.89e-06	5.75e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PTEN—lung cancer	3.88e-06	5.73e-05	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	3.88e-06	5.72e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CASP3—lung cancer	3.84e-06	5.67e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IL2—lung cancer	3.83e-06	5.66e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—IL6—lung cancer	3.82e-06	5.63e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—AKT1—lung cancer	3.79e-06	5.59e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CCND1—lung cancer	3.74e-06	5.52e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MAPK3—lung cancer	3.74e-06	5.52e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3CD—lung cancer	3.73e-06	5.51e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—JUN—lung cancer	3.73e-06	5.51e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	3.72e-06	5.49e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EP300—lung cancer	3.7e-06	5.47e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ALB—lung cancer	3.69e-06	5.44e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MYC—lung cancer	3.63e-06	5.36e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MMP9—lung cancer	3.63e-06	5.36e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	3.62e-06	5.34e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PTEN—lung cancer	3.61e-06	5.33e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—SRC—lung cancer	3.6e-06	5.32e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—TP53—lung cancer	3.59e-06	5.31e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—EGFR—lung cancer	3.55e-06	5.25e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3CB—lung cancer	3.54e-06	5.22e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—AKT1—lung cancer	3.52e-06	5.2e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—VEGFA—lung cancer	3.51e-06	5.18e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PTGS2—lung cancer	3.51e-06	5.18e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—STAT3—lung cancer	3.47e-06	5.13e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—NRAS—lung cancer	3.46e-06	5.12e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3CB—lung cancer	3.45e-06	5.1e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EP300—lung cancer	3.44e-06	5.08e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—HRAS—lung cancer	3.44e-06	5.08e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PTGS2—lung cancer	3.42e-06	5.05e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—KRAS—lung cancer	3.36e-06	4.96e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—SRC—lung cancer	3.35e-06	4.94e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MAPK3—lung cancer	3.32e-06	4.9e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—IL6—lung cancer	3.29e-06	4.86e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—VEGFA—lung cancer	3.26e-06	4.81e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3CB—lung cancer	3.25e-06	4.8e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MYC—lung cancer	3.23e-06	4.76e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—STAT3—lung cancer	3.23e-06	4.76e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PTGS2—lung cancer	3.22e-06	4.76e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—NRAS—lung cancer	3.22e-06	4.75e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EGFR—lung cancer	3.16e-06	4.66e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	3.08e-06	4.55e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MAPK3—lung cancer	3.08e-06	4.55e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PTEN—lung cancer	3.06e-06	4.51e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3CA—lung cancer	3.04e-06	4.49e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—AKT1—lung cancer	3.04e-06	4.48e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MYC—lung cancer	3e-06	4.43e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PTEN—lung cancer	2.98e-06	4.41e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—TP53—lung cancer	2.98e-06	4.41e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—KRAS—lung cancer	2.98e-06	4.4e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EGFR—lung cancer	2.93e-06	4.33e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—EP300—lung cancer	2.92e-06	4.3e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—HRAS—lung cancer	2.85e-06	4.21e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—EP300—lung cancer	2.85e-06	4.2e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PTEN—lung cancer	2.81e-06	4.15e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—KRAS—lung cancer	2.77e-06	4.09e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	2.74e-06	4.04e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IL6—lung cancer	2.73e-06	4.03e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—EP300—lung cancer	2.68e-06	3.96e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—TP53—lung cancer	2.65e-06	3.91e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	2.55e-06	3.76e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—HRAS—lung cancer	2.53e-06	3.74e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—AKT1—lung cancer	2.52e-06	3.72e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—AKT1—lung cancer	2.49e-06	3.67e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—TP53—lung cancer	2.46e-06	3.64e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IL6—lung cancer	2.43e-06	3.58e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—HRAS—lung cancer	2.35e-06	3.48e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IL6—lung cancer	2.25e-06	3.33e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—AKT1—lung cancer	2.24e-06	3.3e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3CA—lung cancer	2.16e-06	3.18e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3CA—lung cancer	2.1e-06	3.11e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—AKT1—lung cancer	2.08e-06	3.07e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3CA—lung cancer	1.98e-06	2.93e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—AKT1—lung cancer	1.76e-06	2.6e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—AKT1—lung cancer	1.72e-06	2.54e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—AKT1—lung cancer	1.62e-06	2.39e-05	CbGpPWpGaD
